Literature DB >> 1691245

Preclinical studies on synergistic effects of IL-1, IL-3, G-CSF and GM-CSF in cynomolgus monkeys.

D Krumwieh1, E Weinmann, B Siebold, F R Seiler.   

Abstract

The regulation of blood cell formation is mediated by a group of polypeptides classified as hematopoietic growth and differentiation factors. Overlapping as well as distinct functions have been described for three of these cytokines: interleukin 3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF). Furthermore, interleukin 1 (IL-1) has been shown to promote hematopoietic regeneration after cytoreductive drug treatment. Evidence has been provided by in vitro studies that combinations of these factors exert a highly synergistic action on the proliferation and differentiation of committed hematopoietic progenitor cells. Additionally, these findings have been supported by studies of in vivo blood cell formation in nonhuman primates. We report here that IL-3 acts synergistically with GM-CSF or G-CSF on myelocytic cell development only if an administration time of eight days of IL-3 is followed by GM-CSF or G-CSF. Short-time IL-3 application of two and four days only resulted in platelet production. The reverse administration schedule did not show synergistically enhanced stimulation of myelocytic cells. However, G-CSF treatment followed by IL-3 did induce a two-fold increase in platelet numbers. This would appear to confirm previously reported in vitro findings that G-CSF shortens the G0 period of human hematopoietic stem cells, which subsequently proliferate in the presence of IL-3. The effects of IL-3 on myelocytic and megakaryocytic development seems to be differently regulated. Whereas, IL-1 failed to display synergistic activity with GM-CSF or G-CSF is sequentially applied. Only simultaneous application either in combination with GM-CSF or with G-CSF demonstrated enhanced efficacy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691245     DOI: 10.1002/stem.5530080722

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN: 0737-1454


  7 in total

Review 1.  G-CSF: status quo and new indications.

Authors:  F Herrmann
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

2.  Preclinical studies and future directions in the development of new hematologic growth factors.

Authors:  S Gillis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

Review 3.  Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions.

Authors:  L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

4.  Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys.

Authors:  A Coscarella; R Liddi; S Bach; S Zappitelli; R Urso; A Mele; R De Santis
Journal:  Mol Biotechnol       Date:  1998-10       Impact factor: 2.695

5.  Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies.

Authors:  Nico Lachmann; Mania Ackermann; Eileen Frenzel; Steffi Liebhaber; Sebastian Brennig; Christine Happle; Dirk Hoffmann; Olga Klimenkova; Doreen Lüttge; Theresa Buchegger; Mark Philipp Kühnel; Axel Schambach; Sabina Janciauskiene; Constanca Figueiredo; Gesine Hansen; Julia Skokowa; Thomas Moritz
Journal:  Stem Cell Reports       Date:  2015-02-10       Impact factor: 7.765

6.  Subcutaneous Four-Week Repeated Dose Toxicity Studies of Rice Cell-Derived Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Rats.

Authors:  Jung Eun Ji; Jung Min Lee; Jong Min Choi; Young Hwa Choi; Eun Kyung Kim; So Jung Chu; Seok Kyun Kim; Kyong Hoon Ahn; Dong Hoon Lee; Ha Hyung Kim; Kyuboem Han; Dae Kyong Kim
Journal:  Toxicol Res       Date:  2008-12-01

7.  PPARs in alveolar macrophage biology.

Authors:  Monica R Smith; Theodore J Standiford; Raju C Reddy
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.